HC Wainwright Forecasts Journey Medical Q1 Earnings

Key Points

• HC Wainwright reiterated a Buy rating with a $13 price target, forecasting Q1 2026 EPS of ($0.05) and a multi‑year EPS ramp (FY2026 $0.16 to FY2030 $2.01), signaling bullish long‑term expectations despite near‑term headwinds.
• Journey reported Q4 EPS of ($0.04) that beat estimates by $0.02 but missed revenue forecasts ($16.08M vs ~$18.86M); the stock is down about 30%, trading near $4.78 with a market cap around $159M and a mixed analyst consensus of "Hold" (3 Buys, 1 Hold, 1 Sell).

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Journey Medical in a research report issued to clients and investors on Wednesday, March 25th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical's Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.17 EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $1.16 EPS, FY2028 earnings at $1.76 EPS, FY2029 earnings at $1.90 EPS and FY2030 earnings at $2.01 EPS.

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Journey Medical in a research report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $13.00.

Journey Medical Stock Down 30.0%

Journey Medical stock opened at $4.78 on Friday. The stock has a market cap of $158.97 million, a PE ratio of -10.17 and a beta of 0.81. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.12 and a current ratio of 1.42. Journey Medical has a one year low of $4.76 and a one year high of $9.56. The stock has a fifty day moving average of $8.00 and a 200 day moving average of $7.80.

Journey Medical (NASDAQ:DERM - Get Free Report) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. The firm had revenue of $16.08 million for the quarter, compared to analysts' expectations of $18.86 million. Journey Medical had a negative return on equity of 51.42% and a negative net margin of 18.48%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Journey Medical in the 2nd quarter worth $29,000. Bank of America Corp DE lifted its position in Journey Medical by 4,707.0% during the second quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock valued at $30,000 after purchasing an additional 4,048 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Journey Medical during the second quarter valued at about $36,000. JPMorgan Chase & Co. bought a new stake in Journey Medical during the second quarter valued at about $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Journey Medical in the second quarter worth about $48,000. Hedge funds and other institutional investors own 7.25% of the company's stock.

Journey Medical News Summary

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Strong Emrosi uptake and FY‑2025 results: Management reported FY2025 revenue of $61.9M, Emrosi generated $14.7M in net revenues with ~53,000 prescriptions filled since its April 2025 launch, and payer access now covers >100M U.S. commercial lives — data that support faster revenue scaling and path to profitability. GlobeNewswire: Full‑Year 2025 Results
• Positive Sentiment: HC Wainwright reiterates Buy and $13 price target with bullish long‑term EPS trajectory: The firm keeps a Buy rating and projects multi‑year EPS growth (FY2027–FY2030 forecasts rising to $1.16 → $2.01), which supports investor optimism about valuation upside versus current levels. MarketBeat: Analyst Note (HC Wainwright)
• Neutral Sentiment: Q4 2025 EPS beat but revenue missed: Journey reported Q4 EPS of ($0.04), beating consensus (‑$0.06) by $0.02, yet revenue of $16.08M missed estimates (~$18.86M). The EPS beat eases near-term concerns, but the top‑line shortfall highlights execution and adoption timing risks. MarketBeat: Q4 Earnings & Call
• Negative Sentiment: HC Wainwright trims some medium‑term estimates: Although still constructive, the firm lowered FY2026–FY2030 estimates slightly (e.g., FY2026 to $0.16 from $0.18; small downticks to FY2027–FY2029 forecasts), indicating tempered near‑term margin/volume assumptions that could limit immediate upside. MarketBeat: Analyst Revisions

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company's product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.